These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8110071)

  • 61. Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis.
    Kabanda A; Jadoul M; Pochet JM; Lauwerys R; van Ypersele de Strihou C; Bernard A
    Kidney Int; 1994 Jun; 45(6):1689-96. PubMed ID: 7933817
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Biocompatibility of hemodialysis membranes: evaluation in an ovine model.
    Burhop KE; Johnson RJ; Simpson J; Chenoweth DE; Borgia J
    J Lab Clin Med; 1993 Feb; 121(2):276-93. PubMed ID: 8433041
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [What is the reason for the increase in beta-2-microglobulin levels in the blood when using cuprophane dialysis membranes?].
    Sulková S; Lapcík O; Votruba T
    Cas Lek Cesk; 1989 Apr; 128(17):520-3. PubMed ID: 2665936
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Comparison of biocompatibility of hemophane, cellulose diacetate and acrilonitile membranes in hemodialysis].
    Germin Petrović D
    Acta Med Croatica; 2004; 58(1):31-6. PubMed ID: 15125391
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes.
    Chenoweth DE; Cheung AK; Henderson LW
    Kidney Int; 1983 Dec; 24(6):764-9. PubMed ID: 6609269
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Changes in the beta 2-microglobulin level during hemodialysis].
    Nikitinskaia LP; Stetsiuk EA; Iarmolinskiĭ IS; Barinov AV; Kon'kova TA
    Urol Nefrol (Mosk); 1990; (5):29-31. PubMed ID: 2264202
    [TBL] [Abstract][Full Text] [Related]  

  • 67. National Kidney Foundation report on dialyzer reuse. Task Force on Reuse of Dialyzers, Council on Dialysis, National Kidney Foundation.
    Am J Kidney Dis; 1997 Dec; 30(6):859-71. PubMed ID: 9398135
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis.
    Küchle C; Fricke H; Held E; Schiffl H
    Am J Nephrol; 1996; 16(6):484-8. PubMed ID: 8955759
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessment of the effects of low dialysate flow rates on removal rates and clearance using high flux membranes.
    Park KI; Tomoyoshi T
    Blood Purif; 1997; 15(3):208-12. PubMed ID: 9262848
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The effects of hemodialysis on platelet activation with new and reprocessed regenerated cellulose dialyzers.
    Windus DW; Atkinson R; Santoro S
    Am J Kidney Dis; 1996 Mar; 27(3):387-93. PubMed ID: 8604708
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration.
    Mason NA; Neudeck BL; Welage LS; Patel JA; Swartz RD
    Clin Nephrol; 2003 Aug; 60(2):96-104. PubMed ID: 12940611
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers.
    Sowinski KM; Mueller BA; Grabe DW; Manley HJ; Frye RF; Bailie GR; Marx MA
    Am J Kidney Dis; 2001 Apr; 37(4):766-76. PubMed ID: 11273877
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The past, present and future of the dialyzer.
    Mineshima M
    Contrib Nephrol; 2015; 185():8-14. PubMed ID: 26023010
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Modified cellulosic dialyzer membranes: an investigative tool in thrombogenicity studies.
    Mahiout A; Meinhold H; Kessel M; Vienken J; Baurmeister U
    ASAIO Trans; 1988; 34(3):878-81. PubMed ID: 3058187
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Potential of dual-skinned, high-flux membranes to reduce backtransport in hemodialysis.
    Soltys PJ; Zydney A; Leypoldt JK; Henderson LW; Ofsthun NJ
    Kidney Int; 2000 Aug; 58(2):818-28. PubMed ID: 10916107
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers.
    McCarthy JT; Jenson BM; Squillace DP; Williams AW
    Am J Kidney Dis; 1997 Apr; 29(4):576-83. PubMed ID: 9100048
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dialyzer membranes as determinants of the adequacy of dialysis.
    Chelamcharla M; Leypoldt JK; Cheung AK
    Semin Nephrol; 2005 Mar; 25(2):81-9. PubMed ID: 15791559
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Iodixanol is readily eliminated by hemodialysis.
    Berg KJ; Rolfsen B; Stake G
    Acta Radiol; 1998 Jul; 39(4):372-4. PubMed ID: 9685821
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Beta2-microglobulin and IgE release during hemodialysis with cuprophan membrane.
    Stefanović V; Savić V; Rajić M; Mitić-Zlatković M
    Int J Artif Organs; 1997 Dec; 20(12):713-4. PubMed ID: 9506789
    [No Abstract]   [Full Text] [Related]  

  • 80. Effect of Membrane Permeability on Cardiovascular Risk Factors and β2m Plasma Levels in Patients on Long-Term Haemodialysis: A Randomised Crossover Trial.
    Chazot C; Kirchgessner J; Pham J; Vo-Van C; Lorriaux C; Hurot JM; Zaoui E; Grassmann A; Jean G; Marcelli D
    Nephron; 2015; 129(4):269-75. PubMed ID: 25825336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.